Ginkgo Bioworks (DNA) vs IRulya Therapeutics (IRLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $432.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | IRLA |
|---|---|---|
| Share price | $7.46 | $39.88 |
| Market cap | $483.54M | $432.36M |
| 1-day change | -9.02% | -0.15% |
| YTD return | -10.23% | — |
| 1-year return | -8.69% | — |
| 5-year return | -98.45% | — |
| EPS (TTM) | $-4.24 | $-162.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | — |
| Revenue growth (YoY) | -25.06% | — |
| Net income (latest FY) | $-312.76M | $-83.98M |
| Operating margin | -185.29% | — |
| Net margin | -183.81% | — |
| 52-week high | $18.22 | $910.00 |
| 52-week low | $5.37 | $15.10 |
| Distance from 52-week high | -59.06% | -95.62% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | +7.24% | +90.90% |
| Average volume | 2.53M | 63.03K |
| Shares outstanding | 53.94M | 10.84M |
| Employees | 485 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
DNA vs IRLA FAQ
Which is bigger, Ginkgo Bioworks or IRulya Therapeutics?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $432.36M for IRulya Therapeutics (IRLA).
Are Ginkgo Bioworks and IRulya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.